Recommended Contraception for Patients with Migraine with Aura
Combined hormonal contraceptives (CHCs) are absolutely contraindicated in patients with migraine with aura due to increased stroke risk; use progestogen-only methods or non-hormonal contraception instead. 1
The Evidence Behind This Recommendation
The most authoritative guideline evidence is unequivocal: combined hormonal contraceptives are contraindicated in women with migraine with aura regardless of any association with their menstrual cycle, owing to an associated increase in the risk of stroke 1. This represents a Category 4 contraindication (unacceptable health risk) in the U.S. Medical Eligibility Criteria 2.
Multiple guidelines from 2008-2024 consistently reinforce this position. The American Heart Association/American Stroke Association guidelines emphasize that migraine with aura coupled with oral contraceptive use significantly increases stroke risk (RR 7.02; 95% CI, 1.51-32.68), and it is reasonable to advise individuals with migraine and stroke who are taking oral contraceptives to switch to another form of birth control 3, 4, 5.
Safe Contraceptive Options
First-Line Recommendations:
Progestogen-only methods:
- Progestogen-only pills (POPs) - drospirenone or norethindrone, <90% effectiveness with typical use 4
- Levonorgestrel IUD - >99% effectiveness 4
- Etonogestrel implant - >99% effectiveness 4
- Depot medroxyprogesterone acetate (DMPA) injection - 93-97% effectiveness 4
Non-hormonal methods:
- Copper IUD - >99% effectiveness 4
- Barrier methods - condoms, diaphragm
- Surgical sterilization - >99% effectiveness 4
These methods carry no increased stroke risk and are safe for patients with migraine with aura 4.
Understanding the Stroke Risk
The stroke risk with CHCs in migraine with aura is dose-dependent and cumulative:
- Higher estrogen content = higher risk: Formulations with ≥50 μg ethinyl estradiol carry the highest risk (RR 4.53), while <50 μg formulations have lower but still elevated risk (RR 2.08) 4
- Risk increases with every 10 μg of estrogen (OR 1.19; 95% CI, 1.16-1.23) 4
- Migraine with aura specifically increases ischemic stroke risk (RR 2.16; 95% CI, 1.53-3.03) compared to migraine without aura (RR 1.23; 95% CI, 0.90-1.69) 5
- Women <45 years with migraine with aura on CHCs have dramatically elevated risk (RR 3.65-9.03 when combined with smoking) 5
Recent 2026 data suggests the absolute risk may be lower with modern ultra-low-dose formulations, but the contraindication remains in current guidelines 6.
Critical Distinction: Migraine WITHOUT Aura
For patients with migraine without aura and no other arterial risk factors (no smoking, no hypertension, age <35), CHCs may be considered 2, 7. However, this is a Category 2-3 classification (benefits generally outweigh risks to risks generally outweigh benefits), requiring careful individualization.
Common Pitfalls to Avoid
Failing to distinguish migraine with aura from migraine without aura - Aura involves specific focal neurological symptoms (visual scintillations, fortification spectra, sensory changes) that develop gradually over 5-60 minutes 8. This distinction is critical for contraceptive safety.
Assuming all hormonal contraception is contraindicated - Only combined hormonal methods (containing estrogen) are contraindicated. Progestogen-only methods are safe and effective.
Overlooking non-hormonal highly effective options - The copper IUD and sterilization offer >99% effectiveness without any hormonal exposure.
Not counseling on additional risk factors - Smoking, hypertension, and age >35 further amplify stroke risk and should be addressed 5.
Special Consideration: Menstrual Migraine Management
If the patient has bothersome menstrual-related migraine attacks, continuous progestogen-only contraception can help by eliminating hormonal fluctuations that trigger attacks 7, 9. This provides both contraception and migraine prophylaxis without the stroke risk of CHCs.